{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T16:19:44Z","timestamp":1774541984437,"version":"3.50.1"},"reference-count":110,"publisher":"The Endocrine Society","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,1,17]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Subclinical hyperthyroidism (SCH) is a laboratory diagnosis defined by a serum thyrotropin (TSH) concentration below the reference range (&amp;lt; 0.4 mU\/L in most assays), and a free thyroxine (FT4) and 3,5,3\u2032-triiodothyronine levels (FT3) in the reference range. Many patients diagnosed with SCH will be clinically euthyroid while others may present with manifestations characteristic of thyroid hormone excess, such as tachycardia, tremor, intolerance to heat, bone density loss, or weight loss. In addition to the laboratory abnormalities, patient factors such as age, symptoms, and underlying heart and bone disease are used to stratify patients for the risk of adverse outcomes and determine the appropriate treatment. Evaluation should include repeat thyroid function tests to document persistent TSH suppression, investigation of the underlying cause, as well as evaluation of the patient's risk of adverse outcomes in the setting of a subnormal TSH. Persistent SCH has been associated with an increased risk of a range of adverse events, including cardiovascular events such as atrial fibrillation and heart failure, bone loss and fracture, and in some studies, cognitive decline. Despite the consistent association of these adverse events with SCH, prospective studies showing improved outcomes with treatment remain limited. Management options include observation without active therapy, radioactive iodine ablation of the thyroid, antithyroid medication, thyroid surgery, or radiofrequency ablation, as appropriate for the patient and clinical setting. The choice of therapy should be guided by the underlying etiology of disease, patient factors, and the risks and benefits of each treatment option.<\/jats:p>","DOI":"10.1210\/clinem\/dgac635","type":"journal-article","created":{"date-parts":[[2022,11,4]],"date-time":"2022-11-04T05:47:14Z","timestamp":1667540834000},"page":"472-482","source":"Crossref","is-referenced-by-count":9,"title":["Approach to the Patient With a Suppressed TSH"],"prefix":"10.1210","volume":"108","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6032-3026","authenticated-orcid":false,"given":"Stephanie Smooke","family":"Praw","sequence":"first","affiliation":[{"name":"Division of Endocrinology, Diabetes, and Metabolism, Department of Medicine, David Geffen School of Medicine at UCLA , Los Angeles, California 90095 , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4638-6645","authenticated-orcid":false,"given":"Gregory A","family":"Brent","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Diabetes, and Metabolism, Department of Medicine, David Geffen School of Medicine at UCLA , Los Angeles, California 90095 , USA"},{"name":"Department of Medicine, VA Greater Los Angeles Healthcare System , Los Angeles, California 90073 , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"80","published-online":{"date-parts":[[2022,11,4]]},"reference":[{"issue":"3","key":"2023011718265122700_dgac635-B1","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1111\/j.1365-2265.2009.03694.x","article-title":"How should we treat patients with low serum thyrotropin concentrations?","volume":"72","author":"Mitchell","year":"2010","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"10","key":"2023011718265122700_dgac635-B2","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1089\/thy.2016.0229","article-title":"2016 American Thyroid Association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis","volume":"26","author":"Ross","year":"2016","journal-title":"Thyroid"},{"issue":"9","key":"2023011718265122700_dgac635-B3","doi-asserted-by":"crossref","first-page":"641","DOI":"10.7326\/M15-0483","article-title":"Screening for thyroid dysfunction: U.S. Preventive Services Task Force recommendation statement","volume":"162","author":"LeFevre","year":"2015","journal-title":"Ann Intern Med"},{"issue":"2","key":"2023011718265122700_dgac635-B4","doi-asserted-by":"crossref","first-page":"262","DOI":"10.4158\/EP151038.PS","article-title":"American Association of Clinical Endocrinologists and American College of Endocrinology position statement on thyroid dysfunction case finding","volume":"22","author":"Hennessey","year":"2016","journal-title":"Endocr Pract"},{"key":"2023011718265122700_dgac635-B5","doi-asserted-by":"crossref","first-page":"l2006","DOI":"10.1136\/bmj.l2006","article-title":"Thyroid hormones treatment for subclinical hypothyroidism: a clinical practice guideline","volume":"365","author":"Bekkering","year":"2019","journal-title":"BMJ"},{"issue":"2","key":"2023011718265122700_dgac635-B6","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1210\/jcem.87.2.8182","article-title":"Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III)","volume":"87","author":"Hollowell","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2023011718265122700_dgac635-B7","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1210\/jc.2013-2409","article-title":"The incidence and prevalence of thyroid dysfunction in Europe: a meta-analysis","volume":"99","author":"Garmendia Madariaga","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2023011718265122700_dgac635-B8","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1111\/j.1365-2265.2010.03908.x","article-title":"Subclinical thyrotoxicosis in an outpatient population\u2014predictors of outcome","volume":"74","author":"Schouten","year":"2011","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"25","key":"2023011718265122700_dgac635-B9","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1056\/NEJMcp1709318","article-title":"Subclinical hyperthyroidism","volume":"378","author":"Biondi","year":"2018","journal-title":"N Engl J Med"},{"issue":"5","key":"2023011718265122700_dgac635-B10","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1210\/er.2018-00119","article-title":"Interferences with thyroid function immunoassays: clinical implications and detection algorithm","volume":"39","author":"Favresse","year":"2018","journal-title":"Endocr Rev"},{"key":"2023011718265122700_dgac635-B11","doi-asserted-by":"crossref","first-page":"e0140475","DOI":"10.1371\/journal.pone.0140475","article-title":"Standardised resting time prior to blood sampling and diurnal variation associated with risk of patient misclassification: results from selected biochemical components","volume":"10","author":"Andersen","year":"2015","journal-title":"PloS One"},{"issue":"11","key":"2023011718265122700_dgac635-B12","first-page":"3700","article-title":"Thyrotropin levels during hydrocortisone infusions that mimic fasting-induced cortisol elevations: a clinical research center study","volume":"82","author":"Samuels","year":"1997","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2023011718265122700_dgac635-B13","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1089\/thy.2016.0457","article-title":"2017 Guidelines of the American Thyroid Association for the diagnosis and management of thyroid disease during pregnancy and the postpartum","volume":"27","author":"Alexander","year":"2017","journal-title":"Thyroid"},{"issue":"9","key":"2023011718265122700_dgac635-B14","doi-asserted-by":"crossref","first-page":"e3562","DOI":"10.1210\/clinem\/dgac223","article-title":"Thyroid hormone abuse in elite sports: the regulatory challenge","volume":"107","author":"Gild","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"2023011718265122700_dgac635-B15","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1056\/NEJMra1901214","article-title":"Drug effects on the thyroid","volume":"381","author":"Burch","year":"2019","journal-title":"N Engl J Med"},{"issue":"14","key":"2023011718265122700_dgac635-B16","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1056\/NEJM199904083401404","article-title":"Central hypothyroidism associated with retinoid X receptor-selective ligands","volume":"340","author":"Sherman","year":"1999","journal-title":"N Engl J Med"},{"issue":"2","key":"2023011718265122700_dgac635-B17","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1159\/000486957","article-title":"2018 European Thyroid Association (ETA) guidelines for the management of amiodarone-associated thyroid dysfunction","volume":"7","author":"Bartalena","year":"2018","journal-title":"Eur Thyroid J"},{"issue":"4","key":"2023011718265122700_dgac635-B18","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1530\/EJE-20-0335","article-title":"Thyrotoxicosis in patients with COVID-19: the THYRCOV study","volume":"183","author":"Lania","year":"2020","journal-title":"Eur J Endocrinol"},{"issue":"4","key":"2023011718265122700_dgac635-B19","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1007\/s11154-020-09615-z","article-title":"Impact of COVID-19 on the thyroid gland: an update","volume":"22","author":"Scappaticcio","year":"2021","journal-title":"Rev Endocr Metab Disord"},{"issue":"1","key":"2023011718265122700_dgac635-B20","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s40249-020-00662-x","article-title":"Expression of the SARS-CoV-2 cell receptor gene ACE2 in a wide variety of human tissues","volume":"9","author":"Li","year":"2020","journal-title":"Infect Dis Poverty"},{"issue":"3","key":"2023011718265122700_dgac635-B21","doi-asserted-by":"crossref","first-page":"bqac004","DOI":"10.1210\/endocr\/bqab004","article-title":"Potential interaction between SARS-CoV-2 and thyroid: a review","volume":"162","author":"Chen","year":"2021","journal-title":"Endocrinology"},{"issue":"2","key":"2023011718265122700_dgac635-B22","doi-asserted-by":"crossref","first-page":"e926","DOI":"10.1210\/clinem\/dgaa813","article-title":"Thyroid dysfunction in relation to immune profile, disease status, and outcome in 191 patients with COVID-19","volume":"106","author":"Lui","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2023011718265122700_dgac635-B23","doi-asserted-by":"crossref","first-page":"e803","DOI":"10.1210\/clinem\/dgaa830","article-title":"Thyroid function before, during, and after COVID-19","volume":"106","author":"Khoo","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2023011718265122700_dgac635-B24","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1089\/thy.2020.0363","article-title":"Thyroid function analysis in 50 patients with COVID-19: a retrospective study","volume":"31","author":"Chen","year":"2021","journal-title":"Thyroid"},{"issue":"1","key":"2023011718265122700_dgac635-B25","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1186\/s12902-021-00896-2","article-title":"Suppression of the hypothalamic-pituitary-thyroid axis is associated with the severity of prognosis in hospitalized patients with COVID-19","volume":"21","author":"Zheng","year":"2021","journal-title":"BMC Endocr Disord"},{"issue":"1","key":"2023011718265122700_dgac635-B26","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/j.1365-2265.1991.tb01739.x","article-title":"Prevalence and follow-up of abnormal thyrotrophin (TSH) concentrations in the elderly in the United Kingdom","volume":"34","author":"Parle","year":"1991","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"10","key":"2023011718265122700_dgac635-B27","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1007\/BF03346431","article-title":"Prevalence and causes of undiagnosed hyperthyroidismin an adult healthy population. The Troms\u00f8 study","volume":"31","author":"Bj\u00f8rndal","year":"2008","journal-title":"J Endocrinol Invest"},{"issue":"14","key":"2023011718265122700_dgac635-B28","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1001\/archinte.167.14.1533","article-title":"Serum thyrotropin measurements in the community: five-year follow-up in a large network of primary care physicians","volume":"167","author":"Meyerovitch","year":"2007","journal-title":"Arch Intern Med"},{"issue":"1","key":"2023011718265122700_dgac635-B29","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1001\/archinte.1991.00400010159025","article-title":"Low serum thyrotropin (thyroid-stimulating hormone) in older persons without hyperthyroidism","volume":"151","author":"Sawin","year":"1991","journal-title":"Arch Intern Med"},{"issue":"9285","key":"2023011718265122700_dgac635-B30","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/S0140-6736(01)06067-6","article-title":"Prediction of all-cause and cardiovascular mortality in elderly people from one low serum thyrotropin result: a 10-year cohort study","volume":"358","author":"Parle","year":"2001","journal-title":"Lancet"},{"issue":"1","key":"2023011718265122700_dgac635-B31","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1210\/jc.2010-0854","article-title":"The Thyroid Epidemiology, Audit, and Research Study (TEARS): the natural history of endogenous subclinical hyperthyroidism","volume":"96","author":"Vadiveloo","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2023011718265122700_dgac635-B32","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1111\/j.1365-2265.2009.03696.x","article-title":"Natural history of subclinical hyperthyroidism in elderly patients with TSH between 0.1 and 0.4 mIU\/L: a prospective study","volume":"72","author":"Rosario","year":"2010","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"1","key":"2023011718265122700_dgac635-B33","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1111\/j.1365-2265.2012.04345.x","article-title":"Serum thyrotrophin at baseline predicts the natural course of subclinical hyperthyroidism","volume":"77","author":"Das","year":"2012","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"7","key":"2023011718265122700_dgac635-B34","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1089\/thy.2005.15.687","article-title":"Observations concerning the natural history of subclinical hyperthyroidism","volume":"15","author":"Woeber","year":"2005","journal-title":"Thyroid"},{"issue":"4","key":"2023011718265122700_dgac635-B35","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1097\/MAJ.0b013e318187e16d","article-title":"An analysis of the natural course of subclinical hyperthyroidism","volume":"337","author":"D\u00edez","year":"2009","journal-title":"Am J Med Sci"},{"issue":"2","key":"2023011718265122700_dgac635-B36","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1001\/archinternmed.2011.677","article-title":"Association between iodinated contrast media exposure and incident hyperthyroidism and hypothyroidism","volume":"172","author":"Rhee","year":"2012","journal-title":"Arch Intern Med"},{"issue":"7","key":"2023011718265122700_dgac635-B37","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1210\/jc.2013-4184","article-title":"Subclinical and overt thyroid dysfunction and risk of all-cause mortality and cardiovascular events: a large population study","volume":"99","author":"Selmer","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"2023011718265122700_dgac635-B38","doi-asserted-by":"crossref","first-page":"4123","DOI":"10.1210\/jc.2012-2268","article-title":"Excess mortality in hyperthyroidism: the influence of preexisting comorbidity and genetic confounding: a Danish nationwide register-based cohort study of twins and singletons","volume":"97","author":"Brandt","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2023011718265122700_dgac635-B39","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1530\/EJE-11-0299","article-title":"A critical review and meta-analysis of the association between overt hyperthyroidism and mortality","volume":"165","author":"Brandt","year":"2011","journal-title":"Eur J Endocrinol"},{"issue":"10","key":"2023011718265122700_dgac635-B40","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1001\/archinternmed.2012.402","article-title":"Subclinical hyperthyroidism and the risk of coronary heart disease and mortality","volume":"172","author":"Collet","year":"2012","journal-title":"Arch Intern Med"},{"issue":"1","key":"2023011718265122700_dgac635-B41","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1530\/EJE-12-0015","article-title":"Subclinical hyperthyroidism and the risk of cardiovascular events and all-cause mortality: an updated meta-analysis of cohort studies","volume":"167","author":"Yang","year":"2012","journal-title":"Eur J Endocrinol"},{"issue":"10","key":"2023011718265122700_dgac635-B42","doi-asserted-by":"crossref","first-page":"e110437","DOI":"10.1371\/journal.pone.0110437","article-title":"Duration of thyroid dysfunction correlates with all-cause mortality. The OPENTHYRO Register cohort","volume":"9","author":"Laulund","year":"2014","journal-title":"PLoS One"},{"issue":"9","key":"2023011718265122700_dgac635-B43","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1002\/jbmr.2244","article-title":"Low serum thyrotropin level and duration of suppression as a predictor of major osteoporotic fractures\u2014the OPENTHYRO Register cohort","volume":"29","author":"Abrahamsen","year":"2014","journal-title":"J Bone Mineral Res"},{"issue":"7","key":"2023011718265122700_dgac635-B44","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1210\/jc.2017-00166","article-title":"Excess mortality in treated and untreated hyperthyroidism is related to cumulative periods of low serum TSH","volume":"102","author":"Lillevang-Johansen","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"issue":"19","key":"2023011718265122700_dgac635-B45","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1056\/NEJM199411103311901","article-title":"Low serum thyrotropin concentrations as a risk factor for atrial fibrillation in older persons","volume":"331","author":"Sawin","year":"1994","journal-title":"N Engl J Med"},{"issue":"9","key":"2023011718265122700_dgac635-B46","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1001\/jama.295.9.1033","article-title":"Thyroid status, cardiovascular risk, and mortality in older adults","volume":"295","author":"Cappola","year":"2006","journal-title":"JAMA"},{"issue":"11","key":"2023011718265122700_dgac635-B47","doi-asserted-by":"crossref","first-page":"832","DOI":"10.7326\/0003-4819-148-11-200806030-00225","article-title":"Meta-analysis: subclinical thyroid dysfunction and the risk for coronary heart disease and mortality","volume":"148","author":"Ochs","year":"2008","journal-title":"Ann Intern Med"},{"issue":"6","key":"2023011718265122700_dgac635-B48","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1111\/j.1365-2265.2010.03882.x","article-title":"Subclinical hyperthyroidism is not associated with progression of cardiac mass and development of left ventricular hypertrophy in middle-aged and older subjects: results from a 5-year follow-up","volume":"73","author":"D\u00f6rr","year":"2010","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"1","key":"2023011718265122700_dgac635-B49","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1111\/j.1365-2265.2005.02422.x","article-title":"Low normal TSH levels are associated with low bone mineral density in healthy postmenopausal women","volume":"64","author":"Kim","year":"2006","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"4","key":"2023011718265122700_dgac635-B50","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1016\/j.bone.2006.12.001","article-title":"The association between serum thyroid-stimulating hormone in its reference range and bone status in postmenopausal American women","volume":"40","author":"Morris","year":"2007","journal-title":"Bone"},{"issue":"3","key":"2023011718265122700_dgac635-B51","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/j.bone.2009.10.031","article-title":"Serum TSH values and risk of vertebral fractures in euthyroid post-menopausal women with low bone mineral density","volume":"46","author":"Mazziotti","year":"2010","journal-title":"Bone"},{"issue":"2","key":"2023011718265122700_dgac635-B52","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1111\/j.1365-2265.2010.03818.x","article-title":"The association between serum thyrotropin (TSH) levels and bone mineral density in healthy euthyroid men","volume":"73","author":"Kim","year":"2010","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"1","key":"2023011718265122700_dgac635-B53","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s40618-017-0753-4","article-title":"Thyroid diseases and bone health","volume":"41","author":"Williams","year":"2018","journal-title":"J Endocrinol Invest"},{"key":"2023011718265122700_dgac635-B54","doi-asserted-by":"crossref","first-page":"873820","DOI":"10.3389\/fendo.2022.873820","article-title":"Endocrine regulation on bone by thyroid","volume":"13","author":"Zhu","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2023011718265122700_dgac635-B55","first-page":"4701","article-title":"Endogenous subclinical hyperthyroidism affects quality of life and cardiac morphology and function in young and middle-aged patients","volume":"85","author":"Biondi","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"2023011718265122700_dgac635-B56","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1055\/s-2004-825925","article-title":"Depression and anxiety in different thyroid function states","volume":"36","author":"Larisch","year":"2004","journal-title":"Horm Metab Res"},{"issue":"3","key":"2023011718265122700_dgac635-B57","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1507\/endocrj.51.311","article-title":"Assessment of anxiety in subclinical thyroid disorders","volume":"51","author":"Sait G\u00f6nen","year":"2004","journal-title":"Endocr J"},{"issue":"11","key":"2023011718265122700_dgac635-B58","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1007\/BF01667147","article-title":"Psychopathological and neuropsychological symptoms in patients with subclinical and remitted hyperthyroidism","volume":"68","author":"Bommer","year":"1990","journal-title":"Klin Wochenschr"},{"issue":"8","key":"2023011718265122700_dgac635-B59","first-page":"2592","article-title":"Minimal cardiac effects in asymptomatic athyreotic patients chronically treated with thyrotropin-suppressive doses of L-thyroxine","volume":"82","author":"Shapiro","year":"1997","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2023011718265122700_dgac635-B60","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1677\/erc.0.0100601","article-title":"Quality of life and psychometric functionality in patients with differentiated thyroid carcinoma","volume":"10","author":"Botella-Carretero","year":"2003","journal-title":"Endocr Relat Cancer"},{"issue":"3","key":"2023011718265122700_dgac635-B61","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1111\/j.1365-2265.2006.02458.x","article-title":"Quality of life in longterm exogenous subclinical hyperthyroidism and the effects of restoration of euthyroidism, a randomized controlled trial","volume":"64","author":"Eustatia-Rutten","year":"2006","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"1","key":"2023011718265122700_dgac635-B62","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1111\/j.1468-1331.2006.01605.x","article-title":"Recommendations for the diagnosis and management of Alzheimer's disease and other disorders associated with dementia: EFNS guideline","volume":"14","author":"Waldemar","year":"2007","journal-title":"Eur J Neurol"},{"issue":"5","key":"2023011718265122700_dgac635-B63","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1210\/jc.2007-1957","article-title":"Health status, mood, and cognition in experimentally induced subclinical thyrotoxicosis","volume":"93","author":"Samuels","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"2023011718265122700_dgac635-B64","doi-asserted-by":"crossref","first-page":"4945","DOI":"10.1210\/jc.2016-2129","article-title":"Subclinical thyroid dysfunction and the risk of cognitive decline: a meta-analysis of prospective cohort studies","volume":"101","author":"Rieben","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"2023011718265122700_dgac635-B65","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1001\/jamainternmed.2021.5078","article-title":"Association of thyroid dysfunction with cognitive function: an individual participant data analysis","volume":"181","author":"van Vliet","year":"2021","journal-title":"JAMA Intern Med"},{"issue":"3","key":"2023011718265122700_dgac635-B66","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1159\/000438750","article-title":"The 2015 European Thyroid Association guidelines on diagnosis and treatment of endogenous subclinical hyperthyroidism","volume":"4","author":"Biondi","year":"2015","journal-title":"Eur Thyroid J"},{"issue":"4","key":"2023011718265122700_dgac635-B67","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1530\/eje.0.1450391","article-title":"Haemodynamic changes following treatment of subclinical and overt hyperthyroidism","volume":"145","author":"Faber","year":"2001","journal-title":"Eur J Endocrinol"},{"issue":"5","key":"2023011718265122700_dgac635-B68","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1089\/thy.2010.0333","article-title":"The influence of subclinical hyperthyroidism on blood pressure, heart rate variability, and prevalence of arrhythmias","volume":"22","author":"Kaminski","year":"2012","journal-title":"Thyroid"},{"issue":"4","key":"2023011718265122700_dgac635-B69","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1210\/jc.2002-021046","article-title":"The effects of early antithyroid therapy for endogenous subclinical hyperthyroidism in clinical and heart abnormalities","volume":"88","author":"Sgarbi","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2023011718265122700_dgac635-B70","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1111\/j.1365-2265.1994.tb02571.x","article-title":"Bone metabolism during anti-thyroid drug treatment of endogenous subclinical hyperthyroidism","volume":"41","author":"Mudde","year":"1994","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"3","key":"2023011718265122700_dgac635-B71","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1007\/s12020-016-1174-4","article-title":"12-month Efficacy of a single radiofrequency ablation on autonomously functioning thyroid nodules","volume":"57","author":"Bernardi","year":"2017","journal-title":"Endocrine"},{"issue":"5","key":"2023011718265122700_dgac635-B72","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1080\/02656736.2018.1430868","article-title":"Nodule size as predictive factor of efficacy of radiofrequency ablation in treating autonomously functioning thyroid nodules","volume":"34","author":"Cesareo","year":"2018","journal-title":"Int J Hyperthermia"},{"issue":"11","key":"2023011718265122700_dgac635-B73","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1007\/s40618-019-01054-1","article-title":"Safety of long-term antithyroid drug treatment? A systematic review","volume":"42","author":"Azizi","year":"2019","journal-title":"J Endocrinol Invest"},{"issue":"1","key":"2023011718265122700_dgac635-B74","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1297\/cpe.26.1","article-title":"Relationship between dose of antithyroid drugs and adverse events in pediatric patients with Graves\u2019 disease","volume":"26","author":"Yasuda","year":"2017","journal-title":"Clin Pediatr Endocrinol"},{"issue":"10","key":"2023011718265122700_dgac635-B75","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1007\/BF03346433","article-title":"Long-term follow-up of patients with hyperthyroidism due to Graves\u2019 disease treated with methimazole. Comparison of usual treatment schedule with drug discontinuation vs continuous treatment with low methimazole doses: a retrospective study","volume":"31","author":"Mazza","year":"2008","journal-title":"J Endocrinol Invest"},{"issue":"12","key":"2023011718265122700_dgac635-B76","doi-asserted-by":"crossref","first-page":"4776","DOI":"10.1210\/jc.2013-2569","article-title":"Analysis of 754 cases of antithyroid drug-induced agranulocytosis over 30 years in Japan","volume":"98","author":"Nakamura","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2023011718265122700_dgac635-B77","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1530\/eje.1.01904","article-title":"Effect of long-term continuous methimazole treatment of hyperthyroidism: comparison with radioiodine","volume":"152","author":"Azizi","year":"2005","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"2023011718265122700_dgac635-B78","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1007\/s12020-013-9895-0","article-title":"Predictors of long-term remission in patients with Graves\u2019 disease: a single center experience","volume":"44","author":"Anagnostis","year":"2013","journal-title":"Endocrine"},{"issue":"1","key":"2023011718265122700_dgac635-B79","first-page":"CD003420","article-title":"Antithyroid drug regimen for treating Graves\u2019 hyperthyroidism","volume":"2010","author":"Abraham","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"2023011718265122700_dgac635-B80","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1007\/s12020-021-02725-x","article-title":"The longer the antithyroid drug is used, the lower the relapse rate in Graves\u2019 disease: a retrospective multicenter cohort study in Korea","volume":"74","author":"Park","year":"2021","journal-title":"Endocrine"},{"issue":"9","key":"2023011718265122700_dgac635-B81","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1089\/thy.2019.0180","article-title":"Increased remission rates after long-term methimazole therapy in patients with Graves\u2019 disease: results of a randomized clinical trial","volume":"29","author":"Azizi","year":"2019","journal-title":"Thyroid"},{"issue":"5","key":"2023011718265122700_dgac635-B82","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1089\/thy.2018.0397","article-title":"Treatment of toxic multinodular goiter: comparison of radioiodine and long-term methimazole treatment","volume":"29","author":"Azizi","year":"2019","journal-title":"Thyroid"},{"issue":"12","key":"2023011718265122700_dgac635-B83","doi-asserted-by":"crossref","first-page":"4549","DOI":"10.1210\/jc.2012-2802","article-title":"2011 Survey of clinical practice patterns in the management of Graves\u2019 disease","volume":"97","author":"Burch","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"2023011718265122700_dgac635-B84","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1089\/thy.2016.0222","article-title":"Antithyroid drugs\u2014the most common treatment for Graves\u2019 disease in the United States: a nationwide population-based study","volume":"26","author":"Brito","year":"2016","journal-title":"Thyroid"},{"issue":"3","key":"2023011718265122700_dgac635-B85","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1089\/thy.2019.0132","article-title":"Patterns of use, efficacy, and safety of treatment options for patients with Graves\u2019 disease: a nationwide population-based study","volume":"30","author":"Brito","year":"2020","journal-title":"Thyroid"},{"issue":"5","key":"2023011718265122700_dgac635-B86","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1089\/thy.2008.0392","article-title":"Second primary malignancy risk after radioactive iodine treatment for thyroid cancer: a systematic review and meta-analysis","volume":"19","author":"Sawka","year":"2009","journal-title":"Thyroid"},{"issue":"2","key":"2023011718265122700_dgac635-B87","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1089\/thy.2019.0205","article-title":"Cancer risk after radioactive iodine treatment for hyperthyroidism: a cohort study","volume":"30","author":"Gronich","year":"2020","journal-title":"Thyroid"},{"issue":"4","key":"2023011718265122700_dgac635-B88","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1001\/jama.280.4.347","article-title":"Cancer mortality following treatment for adult hyperthyroidism. Cooperative Thyrotoxicosis Therapy Follow-up Study Group","volume":"280","author":"Ron","year":"1998","journal-title":"JAMA"},{"issue":"9170","key":"2023011718265122700_dgac635-B89","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1016\/S0140-6736(98)12295-X","article-title":"Cancer incidence and mortality after radioiodine treatment for hyperthyroidism: a population-based cohort study","volume":"353","author":"Franklyn","year":"1999","journal-title":"Lancet"},{"issue":"8","key":"2023011718265122700_dgac635-B90","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1001\/jamainternmed.2019.0981","article-title":"Association of radioactive iodine treatment with cancer mortality in patients with hyperthyroidism","volume":"179","author":"Kitahara","year":"2019","journal-title":"JAMA Intern Med"},{"issue":"9","key":"2023011718265122700_dgac635-B91","doi-asserted-by":"crossref","first-page":"e2125072","DOI":"10.1001\/jamanetworkopen.2021.25072","article-title":"Cancer risk after radioactive iodine treatment for hyperthyroidism: a systematic review and meta-analysis","volume":"4","author":"Shim","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"2","key":"2023011718265122700_dgac635-B92","doi-asserted-by":"crossref","first-page":"e448","DOI":"10.1210\/clinem\/dgab700","article-title":"Does radioactive iodine therapy for hyperthyroidism cause cancer?","volume":"107","author":"Kim","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2023011718265122700_dgac635-B93","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1097\/MED.0000000000000561","article-title":"Cancer incidence and mortality following treatment of hyperthyroidism with radioactive iodine","volume":"27","author":"Evron","year":"2020","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"issue":"5","key":"2023011718265122700_dgac635-B94","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1210\/clinem\/dgab917","article-title":"Nonsurgical management of thyroid nodules: the role of ablative therapies","volume":"107","author":"Stan","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2023011718265122700_dgac635-B95","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1089\/thy.2015.0020","article-title":"2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer","volume":"26","author":"Haugen","year":"2016","journal-title":"Thyroid"},{"issue":"4","key":"2023011718265122700_dgac635-B96","doi-asserted-by":"crossref","first-page":"632","DOI":"10.3348\/kjr.2018.19.4.632","article-title":"2017 Thyroid radiofrequency ablation guideline: Korean Society of Thyroid Radiology","volume":"19","author":"Kim","year":"2018","journal-title":"Korean J Radiol"},{"issue":"4","key":"2023011718265122700_dgac635-B97","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1159\/000508484","article-title":"2020 European Thyroid Association clinical practice guideline for the use of image-guided ablation in benign thyroid nodules","volume":"9","author":"Papini","year":"2020","journal-title":"Eur Thyroid J"},{"issue":"2","key":"2023011718265122700_dgac635-B98","doi-asserted-by":"crossref","first-page":"117","DOI":"10.3348\/kjr.2012.13.2.117","article-title":"Radiofrequency ablation of benign thyroid nodules and recurrent thyroid cancers: consensus statement and recommendations","volume":"13","author":"Na","year":"2012","journal-title":"Korean J Radiol"},{"issue":"5","key":"2023011718265122700_dgac635-B99","first-page":"622","article-title":"American Association of Clinical Endocrinologists, American College of Endocrinology, and Associazione Medici Endocrinologi medical guidelines for clinical practice for the diagnosis and management of thyroid nodules\u20142016 update","volume":"22","author":"Gharib","year":"2016","journal-title":"Endocr Pract"},{"issue":"4","key":"2023011718265122700_dgac635-B100","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/s40618-019-01132-4","article-title":"Radiofrequency ablation of functioning and non-functioning thyroid nodules: a single institution 12-month survey","volume":"43","author":"Cappelli","year":"2020","journal-title":"J Endocrinol Invest"},{"key":"2023011718265122700_dgac635-B101","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1007\/s00330-020-07166-0","article-title":"Efficacy and safety of thermal ablation for autonomously functioning thyroid nodules: a systematic review and meta-analysis","volume":"31","author":"Kim","year":"2021","journal-title":"Eur Radiol"},{"issue":"3","key":"2023011718265122700_dgac635-B102","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1089\/thy.2008.0202","article-title":"Thyroid nodules and related symptoms are stably controlled two years after radiofrequency thermal ablation","volume":"19","author":"Spiezia","year":"2009","journal-title":"Thyroid"},{"key":"2023011718265122700_dgac635-B103","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1089\/thy.2014.0100","article-title":"Radiofrequency ablation for autonomously functioning thyroid nodules: a multicenter study","volume":"25","author":"Sung","year":"2015","journal-title":"Thyroid"},{"issue":"12","key":"2023011718265122700_dgac635-B104","doi-asserted-by":"crossref","first-page":"4439","DOI":"10.1210\/jc.2012-2251","article-title":"Thyroid nodules treated with percutaneous radiofrequency thermal ablation: a comparative study","volume":"97","author":"Faggiano","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"2023011718265122700_dgac635-B105","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1007\/s00268-009-0130-3","article-title":"Radiofrequency ablation for the treatment of autonomously functioning thyroid nodules","volume":"33","author":"Baek","year":"2009","journal-title":"World J Surg"},{"issue":"6","key":"2023011718265122700_dgac635-B106","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1111\/cen.13422","article-title":"Radiofrequency ablation for the management of thyroid nodules: a critical appraisal of the literature","volume":"87","author":"Cesareo","year":"2017","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2023011718265122700_dgac635-B107","doi-asserted-by":"crossref","first-page":"565371","DOI":"10.3389\/fendo.2020.565371","article-title":"Novel approaches for treating autonomously functioning thyroid nodules","volume":"11","author":"Pace-Asciak","year":"2020","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"4","key":"2023011718265122700_dgac635-B108","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s40477-015-0169-y","article-title":"Radiofrequency ablation for thyroid nodules: which indications? The first Italian opinion statement","volume":"18","author":"Garberoglio","year":"2015","journal-title":"J Ultrasound"},{"issue":"4","key":"2023011718265122700_dgac635-B109","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.ejim.2011.03.009","article-title":"Should we treat mild subclinical\/mild hyperthyroidism? No","volume":"22","author":"Vanderpump","year":"2011","journal-title":"Eur J Intern Med"},{"issue":"4","key":"2023011718265122700_dgac635-B110","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.ejim.2011.03.008","article-title":"Should we treat mild subclinical\/mild hyperthyroidism? Yes","volume":"22","author":"Wiersinga","year":"2011","journal-title":"Eur J Intern Med"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgac635\/47128257\/dgac635.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/108\/2\/472\/48746393\/dgac635.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/108\/2\/472\/48746393\/dgac635.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,18]],"date-time":"2023-01-18T03:59:14Z","timestamp":1674014354000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/108\/2\/472\/6795451"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,4]]},"references-count":110,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2022,11,4]]},"published-print":{"date-parts":[[2023,1,17]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgac635","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,2,1]]},"published":{"date-parts":[[2022,11,4]]}}}